Results 31 to 40 of about 4,565 (213)

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections [PDF]

Journal of Clinical Medicine, 2019
This study reports the integrated analysis of two phase III studies of meropenem-vaborbactam in the treatment of acute bacterial infections. Targeting Antibiotic Non-Susceptible Gram-Negative Organisms (TANGO) I compared the clinical efficacy and tolerability of meropenem-vaborbactam and piperacillin-tazobactam in the treatment of complicated urinary ...
Chih-Cheng Lai, Chi-Chung Chen, Hung-Jen Tang   +2 more
openaire   +3 more sources

Global shortage of neonatal and paediatric antibiotic trials: rapid review. [PDF]

, 2017
OBJECTIVES: There have been few clinical trials (CTs) on antibiotics that inform neonatal and paediatric drug labelling. The rate of unlicensed and off-label prescribing in paediatrics remains high.
Barker, CI, Bielicki, JA, Bradley, JS, Folgori, L, Lutsar, I, Sharland, M, Thompson, G   +6 more
core   +4 more sources

In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales from patients with intra-abdominal infections: Results of the study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2020

Journal of Microbiology, Immunology and Infection, 2023
Background: Multi-drug resistant Enterobacterales is a growing health threat. Imipenem/relebactam and meropenem/vaborbactam, are not clinically used in Taiwan and the susceptibility is lack from routine laboratory tests.
Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
doaj   +1 more source

Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018–2022) [PDF]

, 2023
Funding Information: Open access funding provided by Università degli Studi di Torino within the CRUI-CARE Agreement. This research was supported by EU funding within the MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project ...
Almeida, André, Bastos, Paulo, Bianco, Gabriele, Boattini, Matteo, Cavallo, Rossana, Comini, Sara, Corcione, Silvia, Costa, Cristina, De Rosa, Francesco Giuseppe   +8 more
core   +1 more source

New evidence in severe pneumonia: meropenem-vaborbactam

Revista Española de Quimioterapia, 2022
The appearance and spread of new mechanisms of bacterial resistance to antibiotics is a serious health problem. One of the most difficult resistance mechanisms to treat is the production of carbapenemases. Carbapenemase KPC is one of those mechanisms with few therapeutic options.
Forteza Guillot, Maria, Martin Cerezuela, Maria, Ramirez, Paula   +2 more
openaire   +3 more sources

Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations [PDF]

Clinical Infectious Diseases, 2018
Ceftazidime/avibactam and meropenem/vaborbactam are changing the management of invasive infections due to carbapenem-resistant Enterobacteriaceae (CRE), leading to higher rates of clinical cure, decreased mortality, and decreased rates of acute kidney injury compared with colistin-based regimens.
Jason M, Pogue, Robert A, Bonomo, Keith S, Kaye   +2 more
openaire   +2 more sources

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas Aeruginosa [PDF]

, 2021
Background: We aimed to describe the clinical characteristics and outcomes of patients treated with meropenem-vaborbactam (MEV) for a variety of gram-negative infections (GNIs), primarily including carbapenem-resistant Enterobacterales (CRE).
Abbo, Lilian M, Allen, David, Alosaimy, Sara, Amaya, Lee, Athans, Vasilios, Carlson, Travis J, Claeys, Kimberly C, Davis, Susan L, DeRonde, Kailynn, Garey, Kevin W, Jo, Jinhee, Jorgensen, Sarah C.J., Kufel, Wesley D, Lagnf, Abdalhamid M, Miller, Mathew, Molina, Kyle C, Morrisette, Taylor, Mynatt, Ryan, Ortwine, Jessica, Rybak, Michael J, Saw, Stephen, Scipione, Marco R, Vega, Ana D, Venugopalan, Veena, Veve, Michael, Yost, Christine, Zhao, Jing J   +26 more
core   +4 more sources

Bicyclic Boronates as Potent Inhibitors of AmpC, the Class C β-Lactamase from Escherichia coli

Biomolecules, 2020
Resistance to β-lactam antibacterials, importantly via production of β-lactamases, threatens their widespread use. Bicyclic boronates show promise as clinically useful, dual-action inhibitors of both serine- (SBL) and metallo- (MBL) β-lactamases.
Pauline A. Lang, Anete Parkova, Thomas M. Leissing, Karina Calvopiña, Ricky Cain, Alen Krajnc, Tharindi D. Panduwawala, Jules Philippe, Colin W. G. Fishwick, Peteris Trapencieris, Malcolm G. P. Page, Christopher J. Schofield, Jürgen Brem   +12 more
doaj   +1 more source

Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections [PDF]

, 2021
Introduction Infections due to carbapenem-resistant Gram-negative bacteria (CR-GNB) are increasingly frequent events, which are associated with a high mortality rate.
Bassetti, Matteo, Cenderello, Giovanni, Falletta, Antonio, Giacobbe, Daniele R., Vena, Antonio   +4 more
core   +1 more source

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex

Microbiology Spectrum, 2023
As meropenem-clavulanic acid is recommended for the treatment of drug-resistant tuberculosis, the repurposing of new carbapenem combinations may provide new treatment options, including oral alternatives.
Elin Economou Lundeberg, Viktoria Andersson, Maria Wijkander, Ramona Groenheit, Mikael Mansjö, Jim Werngren, Teresa Cortes, Ivan Barilar, Stefan Niemann, Matthias Merker, Claudio U. Köser, Lina Davies Forsman   +11 more
doaj   +1 more source